Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody
This article was originally published in PharmAsia News
Executive Summary
Eisai-subsidiary Morphotek signed an agreement with the U.S. National Cancer Institute Aug. 13 under which the firm will use its proprietary Morphodoma technology to develop novel human monoclonal antibodies as potential therapies for prostate cancer. The deal gives the biotech rights to antibodies for a novel antigen identified by NCI researchers
You may also be interested in...
Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment
TOKYO - Eisai has signed a licensing agreement with Japanese start-up SymBio Pharmaceuticals to jointly develop and commercialize lymphoma treatment bendamustine (SyB L-0501) in Japan
Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment
TOKYO - Eisai has signed a licensing agreement with Japanese start-up SymBio Pharmaceuticals to jointly develop and commercialize lymphoma treatment bendamustine (SyB L-0501) in Japan
Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
Eisai has agreed to pay $325 million for Morphotek, a small biopharmaceutical company with proprietary discovery technologies and an oncology pipeline, the companies announced March 22. The deal is expected to close during Eisai's first quarter of 2007, which begins April 1